Regeneron News

Regeneron, Parabilis Form $2.3B ADC-like Pact

May 18, 2026

Regeneron will pay Parabilis up to $2.3 billion to develop antibody-Helicon conjugates aimed at hard-to-drug intracellular targets.

First Gene Therapy Approved for Hearing Loss

April 23, 2026

FDA approved Regeneron's Otarmeni, first gene therapy for OTOF congenital deafness, via accelerated path using Commissioner's Priority Voucher.

Regeneron Enters Radiopharma via $2.1B Telix Deal

April 13, 2026

Regeneron expands into radiopharmaceuticals via $2.1B biobucks deal with Telix Pharmaceuticals to pair its biologics with Telix's lead-212-based alpha therapies.

Eylea Biosimilar Gains UK/EEA Launch Dates

January 30, 2026

ADVANZ and Alvotech settle Eylea patents with Bayer/Regeneron, enabling UK launch Jan 1 2026 and EEA/Switzerland May 1 2026.